Name PRICE MARKET CAPITALIZATION PRICE TO EARNINGS RATIO DIVIDEND YIELD SYMBOL EXCHANGE PRICE PERCENT DIFFERENCE YEAR TO DATE PRICE PERCENT DIFFERENCE 5 YEAR CHART 1 YEAR CHART

Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Tysabri and Tecfidera. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis.

http://www.biogen.com


BIIB $216.71 -10.17 (-4.48%)
Sector Health Care
Industry Biotech & Pharma
Market Cap 44.63 Billion
EPS 4.77 P/E Ratio 10.04
Previous Earnings Tue, Oct 23, 2018
Latest Earnings Tue, Jan 29, 2019
Dividend --
Ex-Date --
Dividend Pay Date --
Dividend History --

216.71 44.63 10.04 0.00 BIIB NASDAQ -4.48 -28.88 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=BIIB&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=BIIB&exchange=NASDAQ&chart=1

Symbol Surfing has been referenced on Barrons, CNN & Investor Place.

About | Blog | Advertising | Terms | info@symbolsurfing.com

Investing Quotes #Legendary


Information is provided "as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.

Some links on this website are advertisements and/or affiliate links and Symbol Surfing receives compensation.

©2019 Symbol Surfing All Rights Reserved. Privacy Policy | ^Top